University of Virginia Cancer Center Treats First Patients With New TomoTherapy(R) Radiation Delivery Mode

MADISON, WI, Oct 29 (MARKET WIRE) --
TomoTherapy Incorporated (NASDAQ: TOMO) announced today that the first
patients are now being treated with the TomoDirect(TM) radiation therapy
delivery mode at the University of Virginia Cancer Center. The addition
of the TomoDirect modality to the TomoTherapy(R) platform gives
clinicians an efficient new option that expands their ability to fight
cancer.

TomoDirect is a non-rotational delivery mode developed as a clinical
complement to the TomoHelical(TM) continuous 360-degree delivery mode. The
TomoDirect delivery option enables users to quickly plan and deliver
advanced TomoTherapy(SM) radiation treatments with a series of linear beam
paths, rather than a single helical delivery path.

With the TomoDirect mode, clinicians can choose two or more discrete
angles for optimal target coverage and define a modulation level -- or
opt for tissue-compensated 3D conformal delivery -- based on specific
patient therapy goals. Planning and treatment times are significantly
reduced due to the use of far fewer treatment beams, with planning taking
as little as 10 minutes and delivery as little as two minutes.

"The combination of TomoDirect and TomoHelical delivery modes provides
physicians with a broad spectrum of highly conformal image-guided
treatment strategies to match the best technique to our patients' needs,"
said Paul W. Read, M.D., Ph.D., associate professor of Radiation Oncology
at the University of Virginia. "TomoDirect offers static field 3D and
intensity-modulated radiation therapy (IMRT) options that may provide
superior dosimetry to superficial tumors, such as breast cancer. The 3D
delivery capabilities essentially take the TomoTherapy system from one
that is a highly specialized IMRT device to a multifunctional system
capable of treating almost every patient."

TomoDirect and TomoHelical delivery modes both utilize the same binary
multi-leaf collimator and CT-style gantry technology unique to the
TomoTherapy platform. As with the TomoHelical mode, the treatment couch
passes through the bore of the TomoTherapy system during a TomoDirect
delivery. This makes it possible for users to treat a target volume up to
160 cm in length, with no need to reposition the patient, and no field
junctioning required.

Clinicians at the University of Virginia initially will be using the
TomoDirect delivery mode to treat patients with breast cancer, and for
palliative care. According to Dr. Read, "As experience continues to show
us the clinical benefits of TomoDirect, I'm confident in its expanded
application to additional types of disease."

ASTRO Presentation on TomoDirect
Dr. Read will discuss the "Practical
Clinical Implementation of a TomoDirect(TM) Program" in TomoTherapy's
Booth (#1946) at 1 p.m., Sunday, November 1, 2009, during the American
Society for Radiation Oncology's 51st ASTRO Annual Meeting in Chicago.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops,
markets and sells advanced radiation therapy solutions that can be used
to treat a wide variety of cancers, from the most common to the most
complex. The ring gantry-based TomoTherapy(R) platform combines
integrated CT imaging with conformal radiation therapy to deliver
sophisticated radiation treatments with speed and precision while
reducing radiation exposure to surrounding healthy tissue. TomoTherapy's
suite of solutions include its flagship Hi-Art(R) treatment system, which
has been used to deliver more than three million CT-guided, helical
intensity-modulated radiation therapy (IMRT) treatment fractions; the
TomoHD(TM) treatment system, designed to enable cancer centers to treat a
broader patient population with a single device; and the TomoMobile(TM)
relocatable radiation therapy solution, designed to improve access and
availability of state-of-the-art cancer care. TomoTherapy's stock is
traded on the NASDAQ Global Select Market under the symbol TOMO. To learn
more about TomoTherapy, please visit TomoTherapy.com.

Copyright2009 TomoTherapy Incorporated. All rights reserved. The
following marks as used herein in italicized or stylized text are among
trademarks, service marks or registered trademarks of TomoTherapy
Incorporated in the United States and other countries: TomoTherapy, Tomo,
TomoDirect, TomoHelical, TomoHD, TomoMobile, TQA, Hi-Art, and the
TomoTherapy logo.

Investor Contact:
Thomas E. Powell
Chief Financial Officer
608.824.2800
Email Contact

Media Contacts:
Kevin O'Malley
Manager, Corporate Communications
608.824.3384
Email Contact

Susan Lehman
Rockpoint Public Relations
510.832.6006
Email Contact

Copyright 2009, Market Wire, All rights reserved.

-0-